Comparison of Risk of Hospitalization for Acute Kidney Injury Between Patients With Type 2 Diabetes Initiating Saxagliptin and Those Initiating Other Oral Antidiabetic Treatments
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 113,505
- 主要终点
- Hospital admission for acute kidney injury
研究概览
简要总结
The purpose of this study is to compare the incidence of hospitalization for acute kidney injury among patients with type 2 diabetes who are new initiators of Saxagliptin and those who are new initiators of other oral antidiabetic drugs in classes other than Dipeptidyl peptidase IV (DPP4) inhibitors.
详细描述
Prospectively designed retrospective database study. This study will be conducted using administrative claims data and electronic medical records that are collected as part of routine clinical practice.
This will be a prospectively-designed database cohort study comparing hospitalizations for acute kidney injury among new initiators of Saxagliptin compared to those who are new initiators of OADs in classes other than DPP4 inhibitors. The study time frame will be from 2009 through 2014.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older
- •Newly prescribed Saxagliptin or an OAD in a class other than DPP4 inhibitors
- •Enrolled in the respective database for at least 180 days prior to the first prescription of new OAD
排除标准
- •Patients identified with a diagnostic code for acute kidney injury within the 180-day baseline period
- •Patients with DPP4 inhibitor exposure during the baseline period
- •Patients currently using Exenatide or Insulin
结局指标
主要结局
Hospital admission for acute kidney injury
时间窗: 52 months
次要结局
- Deaths due to acute kidney injury(54 months)
- Hospitalizations for acute kidney injury and/or death due to acute kidney injury(54 months)